Virbac is forecast to grow earnings and revenue by 10.4% and 5.3% per annum respectively. EPS is expected to grow by 10.2% per annum. Return on equity is forecast to be 12.9% in 3 years.
Key information
10.4%
Earnings growth rate
10.18%
EPS growth rate
Pharmaceuticals earnings growth
10.1%
Revenue growth rate
5.3%
Future return on equity
12.85%
Analyst coverage
Good
Last updated
29 Jun 2026
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
BATS-CHIXE:VIRPP - Analysts future estimates and past financials data (EUR Millions)
Date
Revenue
Earnings
Free Cash Flow
Cash from Op
Avg. No. Analysts
12/31/2028
1,721
211
168
275
7
12/31/2027
1,640
190
122
247
8
12/31/2026
1,546
167
72
211
8
12/31/2025
1,465
151
97
199
N/A
9/30/2025
1,449
142
93
197
N/A
6/30/2025
1,433
133
88
195
N/A
3/31/2025
1,415
139
106
200
N/A
12/31/2024
1,397
145
124
204
N/A
9/30/2024
1,368
143
99
171
N/A
6/30/2024
1,339
141
74
139
N/A
3/31/2024
1,293
131
66
129
N/A
12/31/2023
1,247
121
59
119
N/A
9/30/2023
1,229
120
69
124
N/A
6/30/2023
1,210
119
78
129
N/A
3/31/2023
1,213
121
62
114
N/A
12/31/2022
1,216
122
45
99
N/A
9/30/2022
1,184
120
38
91
N/A
6/30/2022
1,151
119
31
84
N/A
3/31/2022
1,107
116
57
107
N/A
12/31/2021
1,064
113
83
130
N/A
9/30/2021
1,025
137
80
122
N/A
6/30/2021
985
161
77
113
N/A
3/31/2021
960
148
83
116
N/A
12/31/2020
934
136
90
119
N/A
9/30/2020
944
104
106
133
N/A
6/30/2020
953
72
123
146
N/A
3/31/2020
946
62
116
139
N/A
12/31/2019
938
52
109
132
N/A
9/30/2019
921
43
N/A
119
N/A
6/30/2019
903
34
N/A
106
N/A
3/31/2019
886
27
N/A
95
N/A
12/31/2018
869
20
N/A
84
N/A
9/30/2018
862
8
N/A
93
N/A
6/30/2018
854
-4
N/A
103
N/A
3/31/2018
858
-3
N/A
105
N/A
12/31/2017
862
-3
N/A
108
N/A
9/30/2017
871
16
N/A
112
N/A
6/30/2017
879
35
N/A
117
N/A
3/31/2017
876
35
N/A
130
N/A
12/31/2016
872
35
N/A
142
N/A
9/30/2016
861
30
N/A
119
N/A
6/30/2016
850
26
N/A
95
N/A
3/31/2016
851
18
N/A
71
N/A
12/31/2015
853
9
N/A
46
N/A
9/30/2015
846
21
N/A
59
N/A
Analyst Future Growth Forecasts
Earnings vs Savings Rate: VIRPP's forecast earnings growth (10.4% per year) is above the savings rate (3.4%).
Earnings vs Market: VIRPP's earnings (10.4% per year) are forecast to grow slower than the UK market (11.4% per year).
High Growth Earnings: VIRPP's earnings are forecast to grow, but not significantly.
Revenue vs Market: VIRPP's revenue (5.3% per year) is forecast to grow faster than the UK market (4.7% per year).
High Growth Revenue: VIRPP's revenue (5.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: VIRPP's Return on Equity is forecast to be low in 3 years time (12.9%).
Discover growth companies
7D
1Y
7D
1Y
7D
1Y
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2026/07/08 04:50
End of Day Share Price
2026/07/01 00:00
Earnings
2025/12/31
Annual Earnings
2025/12/31
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Virbac SA is covered by 12 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.